ACT Brief: Digital Twins for Virtual Control Arms, Clinical Tech Stack Evolution, and Universal Flu Vaccine Advances

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new contributed article, researchers demonstrated that digital twin technology can construct virtual standard-of-care arms from historical clinical trial data, reducing recruitment burden and addressing ethical concerns around placebo designs. A digital twin cohort of left-sided RAS wild-type metastatic colorectal cancer patients showed stable efficacy outcomes across cohorts, validating the potential for DT integration across drug discovery and trial conduct.
• In a new Q&A, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, discussed what defines an effective modern tech stack: purpose-built tools that integrate seamlessly, guide users through workflows, and simplify execution rather than add complexity. The biggest gap in current systems is insufficient workflow guidance for busy sites managing multiple trials simultaneously.
• In a new interview from Pharmaceutical Executive, Christopher Locher, PhD, CEO of Versatope Therapeutics, discussed emerging vaccine platforms advancing toward a universal influenza vaccine. Multiple approaches including nanoparticle scaffolds, integrated immunity strategies, and epitope-focusing designs are progressing through development, though challenges remain around correlates of protection, development costs, and regulatory expectations.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.